MedTrace Logo

Study on the Mechanism of Acquired Resistance of Entrectinib

NCT07199959 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2025-09-30

No results posted yet for this study

Summary

The goal of this observational study is to learn about the mechanism of acquired resistance in first line trearment of ROS1-positive NSCLC with entrectinib. The main question it aims to answer is:

what is the acquired resistant mechanism of entrectinib as first line treatment setting in patients?

Tissue or blood samples of participants who have already taken entrectinib as their regular medical care for NSCLC will send for Next gene sequencing for genomic profiles and bioinformatic analysis.

Conditions

  • ROS1 Fusion Positive
  • Non Small Cell Lung Cancer

Interventions

PROCEDURE

venipuncyure

venipuncture as clinical practical setting

DRUG

Entrectinib

600mg, oral, once daily

Sponsors & Collaborators

  • Ruijin Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Shanghai Jiaotong University

    collaborator UNKNOWN

  • Fudan University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-15
Primary Completion
2026-06-30
Completion
2026-12-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07199959 on ClinicalTrials.gov